Lessons for Treating Structural Heart Patients during the COVID-19 Pandemic and Beyond
暂无分享,去创建一个
D. Pinto | K. Ho | R. Laham | Mark K. Tuttle | Duane S Pinto | Marie-France Poulin | Ravikant Sharma | Abel Casso-Dominguez | K. Guibone | Kimberly A. Guibone
[1] F. Welt,et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic , 2020, Journal of the American College of Cardiology.
[2] Marco Valgimigli,et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report From the Bleeding Academic Research Consortium , 2011, Circulation.
[3] Wei Wang,et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.
[4] Arif Subhan. Centers for Medicare & Medicaid Services , 2021, Journal of Clinical Engineering.
[5] M. Mack,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.
[6] F. Welt,et al. Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement , 2020, JACC: Cardiovascular Interventions.
[7] D. Wood,et al. Association Between Wait Time for Transcatheter Aortic Valve Replacement and Early Postprocedural Outcomes , 2019, Journal of the American Heart Association.
[8] Pascal Vranckx,et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. , 2012, Journal of the American College of Cardiology.
[9] F. Welt,et al. Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the COVID-19 Pandemic , 2020, Jacc. Cardiovascular Interventions.